德国CureVac GmbH 
成立于2000年.CureVac有限公司专门从事以化学方法合成酶和RNA分子。 CureVac也进行其在肿瘤治疗领域的研究。

CureVac is an integrated biopharmaceutical company with a pipeline of promising drug candidates. Using its RNA technology platform, CureVac is currently developing therapeutic mRNA vaccines (RNActive®) and vaccine adjuvants, comprised of long, non-coding RNA molecules (RNAdjuvant®). CureVac has an in-house GMP facility for manufacturing of RNActive® and RNAdjuvant® in large scales.